Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells

IL-17 is implicated in the pathogenesis of rheumatoid arthritis (RA) and has previously been shown to be induced by tumor necrosis factor (TNF) in vitro. The aim of this study was to assess the impact of TNF inhibition on IL-17 production in collagen-induced arthritis, a model of RA. TNF blockade using TNFR-Fc fusion protein or anti-TNF monoclonal antibody reduced arthritis severity but, unexpectedly, expanded populations of Th1 and Th17 cells, which were shown by adoptive transfer to be pathogenic. Th1 and Th17 cell populations were also expanded in collagen-immunized TNFR p55−/− but not p75−/− mice. The expression of IL-12/IL-23 p40 was up-regulated in lymph nodes (LN) from p55−/− mice, and the expansion of Th1/Th17 cells was abrogated by blockade of p40. Treatment of macrophages with rTNF also inhibited p40 production in vitro. These findings indicate that at least one of the ways in which TNF regulates Th1/Th17 responses in arthritis is by down-regulating the expression of p40. Finally, although TNF blockade increased numbers of Th1 and Th17 cells in LN, it inhibited their accumulation in the joint, thereby providing an explanation for the paradox that anti-TNF therapy ameliorates arthritis despite increasing numbers of pathogenic T cells.

[1]  Eugene Y. Kim,et al.  Exogenous tumour necrosis factor α induces suppression of autoimmune arthritis , 2008, Arthritis research & therapy.

[2]  M. Feldmann,et al.  Collagen-induced arthritis in C57BL/6 mice is associated with a robust and sustained T-cell response to type II collagen , 2007, Arthritis research & therapy.

[3]  K. Oguchi,et al.  TNF-α Drives Human CD14+ Monocytes to Differentiate into CD70+ Dendritic Cells Evoking Th1 and Th17 Responses , 2007, The Journal of Immunology.

[4]  T. Owens,et al.  Elevated interferon gamma expression in the central nervous system of tumour necrosis factor receptor 1‐deficient mice with experimental autoimmune encephalomyelitis , 2006, Immunology.

[5]  D. Furst,et al.  Problems encountered during anti-tumour necrosis factor therapy. , 2006, Best practice & research. Clinical rheumatology.

[6]  I. Buchan,et al.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. , 2006, JAMA.

[7]  T. Ottenhoff,et al.  Divergent effects of IL‐12 and IL‐23 on the production of IL‐17 by human T cells , 2006, European journal of immunology.

[8]  Ying Wang,et al.  A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17 , 2005, Nature Immunology.

[9]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[10]  H. Ziegler,et al.  Paradoxical Anti-Inflammatory Actions of TNF-α: Inhibition of IL-12 and IL-23 via TNF Receptor 1 in Macrophages and Dendritic Cells1 , 2005, The Journal of Immunology.

[11]  R N Maini,et al.  Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. , 2005, Arthritis and rheumatism.

[12]  M. Feldmann,et al.  TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases , 2003, Nature Medicine.

[13]  M. Feldmann,et al.  Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases. , 2003, Nature medicine.

[14]  C. Löwik,et al.  Interleukin 17 synergises with tumour necrosis factor α to induce cartilage destruction in vitro , 2002 .

[15]  C. Löwik,et al.  Interleukin 17 synergises with tumour necrosis factor alpha to induce cartilage destruction in vitro. , 2002, Annals of the rheumatic diseases.

[16]  O. Nadiv,et al.  Interleukin-17 enhances tumor necrosis factor alpha-induced synthesis of interleukins 1,6, and 8 in skin and synovial fibroblasts: a possible role as a "fine-tuning cytokine" in inflammation processes. , 2001, Arthritis and rheumatism.

[17]  I. Wicks,et al.  Severe inflammatory arthritis and lymphadenopathy in the absence of TNF. , 2001, The Journal of clinical investigation.

[18]  George Kollias,et al.  Uncoupling the Proinflammatory from the Immunosuppressive Properties of Tumor Necrosis Factor (Tnf) at the P55 TNF Receptor Level , 2001, The Journal of experimental medicine.

[19]  J Wagner,et al.  Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. , 2000, Immunity.

[20]  G. Kollias,et al.  Accelerated autoimmunity and lupus nephritis in NZB mice with an engineered heterozygous deficiency in tumor necrosis factor , 2000, European journal of immunology.

[21]  J. Dayer,et al.  Contribution of interleukin 17 to synovium matrix destruction in rheumatoid arthritis. , 2000, Cytokine.

[22]  G. Trinchieri,et al.  Inhibition of IL-12 Production in Human Monocyte-Derived Macrophages by TNF1 , 2000, The Journal of Immunology.

[23]  M. Feldmann,et al.  Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis. , 2000, Arthritis and rheumatism.

[24]  D. Paty,et al.  TNF neutralization in MS , 1999, Neurology.

[25]  P. Miossec,et al.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. , 1999, Arthritis and rheumatism.

[26]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[27]  Yulan He,et al.  IL-17 stimulates the production and expression of proinflammatory cytokines, IL-beta and TNF-alpha, by human macrophages. , 1998, Journal of immunology.

[28]  G. Wong,et al.  TNF is a potent anti-inflammatory cytokine in autoimmune-mediated demyelination , 1998, Nature Medicine.

[29]  F. Breedveld,et al.  Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. , 1996, Arthritis and rheumatism.

[30]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[31]  M. Feldmann,et al.  Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R. Maini,et al.  Successful transfer of collagen‐induced arthritis to severe combined immunodeficient (SCID) mice , 1992, Clinical and experimental immunology.

[33]  C. Jacob,et al.  Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis , 1988, Nature.

[34]  H. Mcdevitt,et al.  Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. , 1988, Nature.